GB1181003A — Therapeutic Compositions
Assigned to Mead Johnson and Co LLC · Expires 1970-02-11 · 56y expired
What this patent protects
1,181,003. Medicines containing ion-exchange resins. MEAD JOHNSON & CO. 20 March, 1967, No. 13049/67. Heading A5B. [Also in Division C3] A therapeutically useful composition comprises a major amount by wt. of a non-toxic strongly basic polystyrene anion exchange resin e.g. a …
USPTO Abstract
1,181,003. Medicines containing ion-exchange resins. MEAD JOHNSON & CO. 20 March, 1967, No. 13049/67. Heading A5B. [Also in Division C3] A therapeutically useful composition comprises a major amount by wt. of a non-toxic strongly basic polystyrene anion exchange resin e.g. a quaternary ammonium chloride substituted polystyrene, cross-linked with not more than 10% by wt. of divinylbenzene and a minor amount of acacia gum, the resin having a molecular weight of >3,000, water content of at least 65% by wt. after equililination with air at 100% relative humidity, the ability to absorb glycocholic acid from aq. solutions thereof, and a particle size such that at least 90% by wt. thereof passes a 200 mesh sieve (U.S. Sieve Standard). The composition may also contain a food flavour, alginic acid salt or ester.
Drugs covered by this patent
- Renvela (SEVELAMER CARBONATE) · Sanofi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.